Which local anesthetic agent is preferred for topical anesthesia during awake fiberoptic intubation due to its rapid onset and minimal systemic toxicity?

Explanation

## Topical Anesthesia in Awake Fiberoptic Intubation **Key Point:** Lidocaine 4% spray is the gold standard for topical anesthesia during awake fiberoptic intubation because it provides rapid onset (1–2 minutes), excellent mucosal penetration, and a wide margin of safety when used in appropriate doses (maximum 400 mg total). ### Why Lidocaine 4% is Preferred | Feature | Lidocaine 4% | Bupivacaine 0.5% | Procaine 2% | |---------|--------------|------------------|-------------| | **Onset** | 1–2 min | 3–5 min | 5–10 min | | **Duration** | 30–60 min | 2–4 hours | 15–30 min | | **Systemic toxicity risk** | Low (rapid metabolism) | Higher (longer duration) | Low (ester) | | **Mucosal penetration** | Excellent | Good | Moderate | | **Clinical use in AFI** | Standard | Avoided (risk of overdose) | Suboptimal (short duration) | **High-Yield:** Lidocaine 4% spray delivers 10 mg per actuation; typical AFI uses 3–4 actuations (30–40 mg) for topical anesthesia, well below the 400 mg safe limit. Bupivacaine is avoided because its long duration and high lipophilicity increase the risk of systemic toxicity if overdosed, and it is not necessary for the brief procedure. **Clinical Pearl:** A combination approach—lidocaine 4% spray for initial topical anesthesia followed by 1–2% lidocaine solution via the fiberoptic scope's working channel for deeper airway anesthesia—optimizes patient comfort and safety.